Literature DB >> 19175498

Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis.

E Bruinstroop1, F A Klok, M A Van De Ree, F L Oosterwijk, M V Huisman.   

Abstract

BACKGROUND: The evidence on the optimal duration of treatment in patients with an idiopathic venous thromboembolic event (VTE) is inconclusive. d-dimer testing to predict recurrent VTE has been evaluated in several studies.
OBJECTIVES: We performed a meta-analysis of studies of patients with idiopathic VTE treated with oral anticoagulation therapy (OAT) to assess the prognostic value of elevated D-dimer levels 1 month after discontinuation of OAT for VTE recurrence. PATIENTS/
METHODS: The MEDLINE, EMBASE and Cochrane databases were searched to identify relevant studies. Studies were eligible for inclusion if they included patients with idiopathic VTE and in addition reported results for this group separately, had measured D-dimer approximately 1 month after discontinuation of OAT and had reported on recurrence of VTE. A random-effects model was used to pool study results.
RESULTS: Data from four studies (1539 patients) were included in the current analysis. All studies reported on the number of recurrent events in the normal and elevated D-dimer groups. Overall, 125 of 751 patients (16.6%) with elevated D-dimer levels experienced recurrent VTE during the period of follow-up compared with 57 of 788 patients (7.2%) with normal D-dimer levels. Elevated D-dimer levels were significantly associated with recurrent VTE (odds ratio , 2.36; 95% CI, 1.65 to 3.36).
CONCLUSIONS: Elevated d-dimer levels measured 1 month after discontinuation of OAT identify patients with idiopathic VTE at higher risk of recurrence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19175498     DOI: 10.1111/j.1538-7836.2009.03293.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  14 in total

Review 1.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

2.  Age and gender specific cut-off values to improve the performance of D-dimer assays to predict the risk of venous thromboembolism recurrence.

Authors:  Cristina Legnani; Michela Cini; Benilde Cosmi; Paolo Carraro; Armando Tripodi; Nicoletta Erba; Gualtiero Palareti
Journal:  Intern Emerg Med       Date:  2011-05-17       Impact factor: 3.397

3.  Optimal duration of anticoagulation after venous thromboembolism.

Authors:  Samuel Z Goldhaber; Gregory Piazza
Journal:  Circulation       Date:  2011-02-15       Impact factor: 29.690

4.  Overall haemostatic potential (OHP) assay can risk stratify for venous thromboembolism recurrence in anticoagulated patients.

Authors:  Julie Wang; Hui Yin Lim; Rowena Brook; Jeffrey Lai; Harshal Nandurkar; Prahlad Ho
Journal:  J Thromb Thrombolysis       Date:  2022-07-31       Impact factor: 5.221

5.  [Treatment of venous thromboembolism].

Authors:  A Willeke; E Lindhoff-Last
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

6.  Thrombosis Risk History and D-dimer Levels in Asymptomatic Individuals with Prader-Willi Syndrome.

Authors:  Lisa Matesevac; Jennifer L Miller; Shawn E McCandless; Jaret L Malloy; Jessica E Bohonowych; Caroline Vrana-Diaz; Theresa V Strong
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.241

7.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang
Journal:  Blood Adv       Date:  2020-10-13

8.  Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).

Authors:  Jayne Tullett; Ellen Murray; Linda Nichols; Roger Holder; Will Lester; Peter Rose; F D Richard Hobbs; David Fitzmaurice
Journal:  BMC Cardiovasc Disord       Date:  2013-03-09       Impact factor: 2.298

9.  Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach.

Authors:  Maura Marcucci; Alfonso Iorio; James Douketis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-04

Review 10.  Recurrent venous thromboembolism: what is the risk and how to prevent it.

Authors:  Gualtiero Palareti
Journal:  Scientifica (Cairo)       Date:  2012-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.